Innovita Biological Technology Co., Ltd. Class A
SSSE:68825348.55
CNY
-1.49
(-2.98%)
ISIN
CNE100005Q14
Return %
Stock
S&P 500
1Y
49.80
14.20
3Y
138.34
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xiu Jie Zhang
- Full Time Employees
- 571
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Beijing China
- IPO Date
- Jul 28, 2022
- Website
- innovita.com.cn
- Similar Companies
- Business
- Innovita Biological Technology Co., Ltd. is an in vitro diagnostic biopharmaceutical enterprise that specializes in the research, development, manufacturing, and commercialization of point-of-care testing rapid diagnostic reagents and analytical instruments. Founded in 2006 and headquartered in Beijing, China, the company operates core research and production facilities through its primary subsidiary Innovita (Tangshan) Biological Technology Co., Ltd., alongside international subsidiaries including Innovita Biotech Pte. Ltd., IB Global (HK) Co., Ltd., and Innotech Bio Corporation. The company develops and manufactures diagnostic solutions across multiple technical platforms, including colloidal gold immunochromatography, dry chemical immunoassay, fluorescence immunochromatography, chemiluminescence immunoassay, real-time polymerase chain reaction molecular diagnostics, and digital single-molecule array technology. Innovita's primary product portfolio encompasses respiratory infection diagnostic tests, featuring multi-pathogen antigen combo test kits and real-time PCR nucleic acid assays for Influenza A virus, Influenza B virus, Respiratory Syncytial Virus, SARS-CoV-2, Adenovirus, Human Metapneumovirus, Parainfluenza virus, and Mycoplasma pneumoniae; neurology and brain health diagnostics, including ultra-sensitive blood-based biomarker assay kits and digital single-molecule immunoassay analyzers for phosphorylated Tau 217, phosphorylated Tau 181, neurofilament light chain, and glial fibrillary acidic protein; gastrointestinal disease diagnostics, including Helicobacter pylori antigen tests, fecal occult blood tests, and rotavirus/adenovirus/norovirus rapid antigen combo kits; reproductive health and TORCH screening assays, including Human Chorionic Gonadotropin pregnancy test kits, Luteinizing Hormone ovulation tests, and antibody detection panels for Toxoplasma gondii, Rubella virus, Cytomegalovirus, and Herpes Simplex Virus; infectious disease diagnostics, including screening kits for Hepatitis B, Hepatitis C, Human Immunodeficiency Virus, Treponema pallidum, Dengue virus, Malaria, and Chikungunya virus; and diagnostic instrumentation, including portable fluorescence immunoassay analyzers and automated digital POCT reading systems. Innovita serves public and private hospitals, primary healthcare clinics, emergency medical departments, independent clinical laboratories, and retail pharmacy networks across mainland China, while distributing products internationally across Southeast Asia, Europe, the Middle East, and Latin America. In recent developments, Innovita launched a strategic expansion into neurodegenerative disease diagnostics by executing a technology cooperation agreement with Quanterix Corporation to commercialize Simoa single-molecule technology in China, successfully securing Class III medical device registrations for its digital single-molecule immunoassay analyzer and ultra-sensitive blood-based Alzheimer's disease biomarker assays. In addition, the company expanded its molecular diagnostic portfolio by obtaining regulatory approvals for combined Influenza A/B and Respiratory Syncytial Virus nucleic acid test kits, broadened its international footprint by securing multiple product registrations in Southeast Asian markets such as Thailand and Malaysia, established omnichannel distribution partnerships with AliHealth and Jointown Pharmaceutical Group to enhance direct-to-consumer and pharmacy channel reach, and implemented broad-based equity incentive plans to support long-term research and development initiatives.